




**CME FOUNDATION OF INDIA**



**NOVEL THERAPY TO  
TREAT CKD ANEMIA IN INDIA**

**EVENT REPORT**

## About Workshop

The **CME Foundation of India**, organized an academic workshop on **Novel Therapy to Treat CKD Anemia in India** on 17<sup>th</sup> January 2026 at ESIC Kamgar Hospital, Mulund, Mumbai. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

The workshop was attended by physicians and nephrologists from ESIC Hospital and surrounding centers. The session by **Dr. Haresh Dodeja**, covered multiple aspects of CKD anemia management such as understanding the growing challenge in CKD anemia, limitations of current therapies, desidustat as a novel therapy in CKD management, its mechanism, and practical integration in clinical practice.

**Date:** 17<sup>th</sup> January 2026

**Venue:** ESIC Kamgar Hospital, Mulund, Mumbai

**No. of participants:** 16

## Agenda

**Date:** 17<sup>th</sup> January 2026

**Time:** 1:00 p.m. to 2:00 p.m.

Topics	Speaker	Timings
Registration		1:00 p.m. – 1:10 p.m.
Welcome Note		1:10 p.m. – 1:15 p.m.
Novel Therapy to Treat CKD Anemia in India	Dr. Haresh Dodeja M.B.B.S., M.D. (Medicine), D.N.B. (Nephrology)	1:15 p.m. – 1:55 p.m.
Vote of Thanks		1:55 p.m. – 2:00 p.m.

# Summary of the Novel Therapy to Treat CKD Anemia in India

## The Growing Challenge of CKD-Related Anemia

Dr. Haresh Dodeja opened the session by highlighting the significant burden of chronic kidney disease (CKD)-related anemia in India, emphasizing its profound impact on patient outcomes, overall quality of life, and healthcare costs. He explained that anemia in CKD is a complex, multifactorial condition arising from factors such as iron deficiency, chronic inflammation, and reduced erythropoietin production. Dr. Haresh Dodeja stressed that these overlapping causes make anemia management challenging and underscored the urgent need for innovative treatment strategies that go beyond conventional therapies.

## Gaps in Current Anemia Management

The discussion then focused on existing treatment approaches, including erythropoiesis-stimulating agents (ESAs) and iron supplementation. Dr. Haresh Dodeja highlighted several limitations associated with these therapies, such as inconsistent efficacy, potential safety concerns, and limited accessibility within the Indian healthcare context. He pointed out that these challenges often result in suboptimal hemoglobin control, frequent treatment adjustments, and lower patient adherence, all of which contribute to persistent clinical gaps in CKD anemia management.

## Desidustat: A Novel Therapeutic Approach

A major highlight of the workshop was Desidustat, a novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Haresh Dodeja explained that Desidustat works by stimulating the body's natural erythropoietin production, enhancing iron utilization, and lowering hepcidin levels. By addressing multiple mechanisms underlying anemia in CKD, Desidustat presents a potentially safer, more convenient oral alternative to traditional ESA therapy, reducing the need for frequent injections and potentially improving patient adherence.

## Evidence Supporting Desidustat Use

Dr. Haresh Dodeja reviewed pivotal clinical trial results demonstrating Desidustat's efficacy in raising and maintaining stable hemoglobin levels across diverse patient populations. He highlighted its favorable safety and tolerability profile. In addition, he shared insights from real-world practice that support Desidustat's effectiveness in both dialysis-dependent and non-dialysis CKD patients.

## **Practical Integration into Clinical Practice**

The session also included practical guidance on patient selection, dosing strategies, monitoring parameters, and considerations for incorporating Desidustat into routine CKD anemia management. Participants explored actionable insights to optimize therapy, enhance patient adherence, and improve overall outcomes, reflecting a patient-centered approach to modern anemia care.

**At the end of the Conclave, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the Conclave.**

## Snapshots of Success

### Venue



### Lecture on Novel Therapy to Treat CKD Anemia in India









Developed by:

## **CME FOUNDATION OF INDIA**

Building "A" Sahney Business Centre, 27 Kirol Road, Vidyavihar (W), Mumbai - 400086  
Tel: +91 22 61798600 | Website: [www.cmefi.co.in](http://www.cmefi.co.in)